Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Preferal biopesticide close to EU renewal

Proposals to renew the EU approval of the bioinsecticide, Isaria fumosorosea strain Apopka 97 (formerly Paecilomyces fumosoroseus Apopka 97), have been voted through by the EU Standing Committee on Plants, Animals, Food and Feed. The active ingredient is for use on cucumbers and tomatoes grown in greenhouses, and is sold as Preferal. The renewal application was submitted by Mitsui & Co subsidiary Mitsui Agriscience. The European Commission proposals recognise the ai as low-risk and eligible for a 15-year approval period, rather than the standard ten. It would commence on January 1st 2016, the day after the current approval expires. The decision requires formal adoption before coming into force. In 2001, P fumosoroseus became the first biopesticide to gain EU approval, and was introduced for use against greenhouse whiteflies by Belgian company Biobest (Westerlo). Biobest licensed the ai for European development from Thermo Trilogy, now Mitsui & Co subsidiary Certis.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG021629

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel